Tuberculosis and Rheumatoid Arthritis in the Elderly

  • Eduardo M. Acevedo-VásquezEmail author
  • Darío Ponce de León
  • Rocío V. Gamboa-Cárdenas


An infectious etiology for rheumatic diseases has been postulated for many decades. This chapter will review the link between tuberculosis and rheumatoid arthritis, and how the aging immune system contributes to the clinical response to mycobacterium tuberculosis infection. The relationship between anti-TNF therapies and tuberculosis will also be discussed.


Tuberculosis Latent tuberculosis infection Rheumatoid arthritis Immunosenescense TNF-antagonists 


  1. 1.
    Gomez-Reino J, Carmona L, Rodríguez V, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. A multicenter active-surveillance report Arthritis Rheum. 2003;48:2122–7.Google Scholar
  2. 2.
    Mobley JL. Is Rheumatoid Arthritis a consequence of natural selection for enhanced tuberculosis resistance? Med Hypotheses. 2004;62:839–43.PubMedCrossRefGoogle Scholar
  3. 3.
    Zimmerman MR. Pulmonary and osseous tuberculosis in an Egyptian mummy. Bull NY Acad Med. 1979;55:604–8.Google Scholar
  4. 4.
    Gomez J, Mendonça de Souza S. Prehistoric Tuberculosis in America: Adding Comments to Literature Review. Mem Inst Oswaldo Cruz, Rio de Janeiro. 2002;98:S151–59.CrossRefGoogle Scholar
  5. 5.
    Acevedo-Vásquez E, Ponce De León D, Gamboa R. La tuberculosis como enfermedad emergente asociada al tratamiento médico de la artritis reumatoide. In: Caballero CV, editor. Retos para el diagnóstico y tratamiento de la artritis reumatoide en America Latina. Barranquilla, Colombia: Ediciones Uninorte; 2006. p. 348–71.Google Scholar
  6. 6.
    World Health Organization. Global tuberculosis control: a short update to the 2009 report. Estimated epidemiological burden of TB, all forms, 1990–2008 (2009).Google Scholar
  7. 7.
    Ministerio de Salud del Perú. Prevención y control de tuberculosis. Estrategia Sanitaria Nacional de Tuberculosis. Informe Anual. (2006).
  8. 8.
    Gavazzi G, Herrmann F, Krause K. Aging and Infectious Diseases in the Developing World. Clin Infect Dis. 2004;39:83–91.PubMedCrossRefGoogle Scholar
  9. 9.
    Center for Diseases Control and Prevention (CDC). National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Reported Tuberculosis in the United States, 2007. (2008).
  10. 10.
    Rothschild B, Rothschild C, Helbling M. Unified Theory of the Origins of Erosive Arthritis: Conditioning as a Protective/Directing Mechanism? J Rheumatol. 2003;30:2095–102.PubMedGoogle Scholar
  11. 11.
    Pagel W, Simmonds FAH, Macdonald N, Nassau E. Pulmonary tuberculosis: bacteriology, pathology, diagnosis, management, epidemiology, and prevention. 4th ed. London: Oxford University Press; 1964.Google Scholar
  12. 12.
    Weyand C, Fulbright J, Goronzy J. Immunosenescence, autoimmunity, and rheumatoid arthritis. Exp Gerontol. 2003;38:833–41.PubMedCrossRefGoogle Scholar
  13. 13.
    Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol. 2004;5:133–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Thewissen M, Somers V, Venken K, et al. Analysis of Immunosenescence markers in Patients with autoimmnune disease. Clin Immunol. 2007;123:209–18.PubMedCrossRefGoogle Scholar
  15. 15.
    Weyand CM, Goronzy JJ. Premature Immunosenescence in Rheumatoid Arthritis. J Rheumatol. 2002;29:1141–6.PubMedGoogle Scholar
  16. 16.
    Crowson CM, Liang KP, Therneau TM, Kremers HM, Gabriel SH. Could Accelerated Aging Explain the Excess Mortality in Patients with Seropositive Rheumatoid Arthritis? Arthritis Rheum. 2010;62:378–82.PubMedCrossRefGoogle Scholar
  17. 17.
    Flynn JL, Chan J. Immunology of tuberculosis. Ann Rev Immunol. 2001;19:93–129.CrossRefGoogle Scholar
  18. 18.
    Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A, Cucho M, Alfaro J, Perich R, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis. 2005;64:1360–1.CrossRefGoogle Scholar
  19. 19.
    Carmona L, Hernández-García C, Vadillo C. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol. 2003;30:1436–9.PubMedGoogle Scholar
  20. 20.
    Yoshinaga Y, Tatsuya K, Tomoko M, et al. Clinical characteristics of Mycobacterium rheumatoid arthritis patients. Mod Rheumatol. 2004;14:143–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Yamada T, Nakajima A, Inoue E, et al. Elevated risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis. 2006;65:1661–3.PubMedCrossRefGoogle Scholar
  22. 22.
    Wolfe F, Michaud K, Anderson J, Urbanisky K. Tuberculosis infection in patients with rheumatoid artritis and the effect of infliximab therapy. Arthritis Rheum. 2004;50:372–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Gamboa R, Acevedo-Vásquez E, Gutiérrez C, Ponce de León D, et al. Riesgo de enfermedad tuberculosa en pacientes con Artritis Reumatoide. An Fac Med. (Universidad Nacional Mayor de San Marcos, Perú) 2006;67:310–7.Google Scholar
  24. 24.
    Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol. 2007;34: 706–11.PubMedGoogle Scholar
  25. 25.
    Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52:1986–92.PubMedCrossRefGoogle Scholar
  26. 26.
    St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432–43.PubMedCrossRefGoogle Scholar
  27. 27.
    Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group Lancet. 1999;354:1932–9.Google Scholar
  28. 28.
    Schneeweiss S. Anti Tumor Necrosis Factor Therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:1754–64.PubMedCrossRefGoogle Scholar
  29. 29.
    Burmester GR, Mariette X, Montecucco C, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis. 2007;66:732–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Weinblatt M, Keystone E, Furst D, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35–45.PubMedCrossRefGoogle Scholar
  31. 31.
    Furst D, Schiff M, Fleischmann R, et al. Adalimumab, a Fully Human Anti–Tumor Necrosis Factor-α Monoclonal Antibody, and Concomitant Standard Antirheumatic Therapy for the Treatment of Rheumatoid Arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003;30:2563–71.PubMedGoogle Scholar
  32. 32.
    Breedveld F, Weisman M, Kavanaugh A, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37.PubMedCrossRefGoogle Scholar
  33. 33.
    Fleischmann R, Baumgartner S, Weisman M. Liu, T. Long term safety of etanercept in elderly subjects Ann Rheum Dis. 2006;65:379–38.Google Scholar
  34. 34.
    Van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54:1063–74.PubMedCrossRefGoogle Scholar
  35. 35.
    Klareskog L, Van der Heijde D, Jager J, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet. 2004;363:675–81.PubMedCrossRefGoogle Scholar
  36. 36.
    Tubach S, Salmon D, Ravaud P, Allanore Y, Goupille P. Risk of Tuberculosis Is Higher With Anti–Tumor Necrosis Factor Monoclonal Antibody Therapy Than With Soluble Tumor Necrosis Factor Receptor Therapy. Arthritis Rheum. 2009;60:1884–94.PubMedCrossRefGoogle Scholar
  37. 37.
    Dixon WG, Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy:results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69:522–28.PubMedCrossRefGoogle Scholar
  38. 38.
    Wang C, Chen H, Yang C, et al. The Impact of Age on the Demographic, Clinical, Radiographic Characteristics and Treatment Outcomes of Pulmonary Tuberculosis Patients in Taiwan. Infection. 2008;36:335–40.PubMedCrossRefGoogle Scholar
  39. 39.
    Vadillo C, Hernández-García C, Pato E, et al. Incidence and characteristics of tuberculosis in patients with autoimmune rheumatic diseases. Rev Clin Esp. 2003;203:178–82.CrossRefGoogle Scholar
  40. 40.
    Yun JE, Lee SW, Kim TH, et al. The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol. 2002;20:127–32.PubMedGoogle Scholar
  41. 41.
    Gamboa R, Ugarte M, Acevedo E, Medina M, Gutierrez C, Pastor C, et al. Tuberculosis is a Lung Non cavitated Disease in Rheumatoid Arthritis Patients non users of biologic therapy in a high prevalence tuberculosis country. J Clin Rheumatol. 2008;14:S37.Google Scholar
  42. 42.
    Gardam M, Keystone E, Menzies R. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:1–14.CrossRefGoogle Scholar
  43. 43.
    Barnetson R, Gawkrodger D, Britton W. In: Roitt I, Brostoff J, Male D, editors. Hypersensitivity type IV, in immunology. London, UK: Mosby; 1996.Google Scholar
  44. 44.
    Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med. 1999;159:15–21.PubMedGoogle Scholar
  45. 45.
    Winthrop KL et al. Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum. 2005;52:2968–74.PubMedCrossRefGoogle Scholar
  46. 46.
    Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146:340–54.PubMedGoogle Scholar
  47. 47.
    Matulis G, Juni P, Villiger PM, et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: Performance of a Mycobacterium tuberculosis antigen-specific interferon γ assay. Ann Rheum Dis. 2008;67:84–90.PubMedCrossRefGoogle Scholar
  48. 48.
    Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, et al. Comparison of an Interferon-γ Assay with Tuberculin Skin Testing for Detection of Tuberculosis (TB) Infection in Patients with Rheumatoid Arthritis in a TB-Endemic Population. J Rheumatol. 2008;35:776–81.PubMedGoogle Scholar
  49. 49.
    Centers for Disease Control and Prevention. Guidelines for the investigation of contacts of persons with infectious tuberculosis; recommendations from the National Tuberculosis Controllers Association and CDC, and Guidelines for using the QuantiFERON®-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR. 2005;54(RR-15):49–55.Google Scholar
  50. 50.
    Kobashi Y, Mouri K, Yagui S, et al. Clinical Utility of the QuantiFERON TB-2G Test for Elderly Patients with Active Tuberculosis. Chest. 2008;133:1196–202.PubMedCrossRefGoogle Scholar
  51. 51.
    Acevedo-Vasquez E, Ponce de Leon D, Gamboa-Cardenas R. Latent infection and tuberculosis disease in rheumatoid arthritis patients. Rheum Dis Clin North Am. 2009;35:163–81.PubMedCrossRefGoogle Scholar
  52. 52.
    British Thoracic Society Standards of Care. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF a treatment. Thorax; 2005;60:800–5.CrossRefGoogle Scholar
  53. 53.
    Salmon D. on behalf of the GTI and AFSSAPS. Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine. 2002;69:170–2.CrossRefGoogle Scholar
  54. 54.
    Diel R, Hauer B, Loddenkemper R, Manger B, Krüger K. New TB testing recommendations for autoimmune diseases, Germany (Recommendations for tuberculosis screening before initiation of TNF-α-inhibitor treatment in rheumatic diseases). Zeitschrift für Rheumatologie. 2009;68(5):411–16.PubMedCrossRefGoogle Scholar
  55. 55.
    Beglinger C, Dudler J, Mottet C, Nicod L, Seibold F, Villiger P, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly. 2007;137:620–2.PubMedGoogle Scholar
  56. 56.
    KNCV/EuroTB Workshop. Use of gamma-interferon assays in low- and medium-prevalence countries in Europe: a consensus statement of a Wolfheze Workshop organized by KNCV/EuroTB, Vilnius Sept 2006. Euro Surveill. 12:E070726.2 (2007).Google Scholar
  57. 57.
    Kucharz E et al. Recommendations for prophylaxis and management of tuberculosis in patients treated with TNFa antagonists. Reumatologia. 2008;2:53–4.Google Scholar
  58. 58.
    Commissie voor Praktische Tuberculosebestrijding (CPT). Plaatsbepaling van de Interferon Gamma Release Assays bij de diagnostiek van tuberculose. [Dutch Committee for Practical Tuberculosis Control. Positioning of Interferon Gamma Release Assays in the diagnosis of tuberculosis]. October 2007 (2007).Google Scholar
  59. 59.
    Health Protection Agency. Position Statement on the use of Interferon Gamma Assay (IGRA) test for Tuberculosis (TB), October 2007. Available online at (2007).
  60. 60.
    National Institute for Health and Clinical Excellence (NICE) UK. Tuberculosis. Clinical diagnosis and management of tuberculosis and measures for the prevention and control March 2006 (2006).Google Scholar
  61. 61.
    Canadian Tuberculosis Committee. Updated recommendations on interferon gamma release assays for latent tuberculosis infection. An Advisory Committee Statement (ACS). Can Commun Dis Rep. 2008;34(ACS-6):1–13.Google Scholar
  62. 62.
    Committee of Prevention, Japanese Society of Tuberculosis. Japan Guidelines for contact investigation 2007: Japan Anti-tuberculosis association. Kekkaku. 2006;81:393–7.Google Scholar
  63. 63.
    Recommendations of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Diagnosis and Treatment of Tuberculosis. Arch Bronconeumol. 2008;44:551–66.Google Scholar
  64. 64.
    Australian Government, Department of Health and Ageing. National Tuberculosis Advisory Committee: Position statement on Interferon-gamma release immunoassays in the detection of latent tuberculosis infection, October 2007 (2007).Google Scholar
  65. 65.
    Solovic I. National Institute for TB. Slovakia: Lung Diseases and Thoracic Surgery; 2008.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Eduardo M. Acevedo-Vásquez
    • 1
    Email author
  • Darío Ponce de León
  • Rocío V. Gamboa-Cárdenas
  1. 1.School of MedicineUniversidad Nacional Mayor de San MarcosLimaPeru

Personalised recommendations